Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility

AmgenAmgen Inc. (Nasdaq: AMGN) and Boehringer Ingelheim have signed an agreement under which Boehringer Ingelheim will acquire Amgen's rights in and substantially all assets at Amgen's Fremont California development and manufacturing facility.

The transaction has been approved by the board of directors of each company and is expected to close in March of this year. The Amgen Fremont facility currently employs approximately 360 employees and is a state-of-the-art, 100,000-square-foot manufacturing facility with pilot plant and process development labs.

"With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family of companies," said Prof. Dr. Wolfram Carius, Boehringer Ingelheim Board of Managing Directors. "The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global Contract Manufacturing Business including new biological entity process development and manufacturing efforts. We greatly value our relationship with Amgen and are enthusiastic about joining the San Francisco Bay Area biotechnology community and for the opportunity to better serve our current and future contract manufacturing customers."

Boehringer Ingelheim has been a contract manufacturer for Amgen for more than ten years.

"We are pleased to be able to build upon a successful contract manufacturing relationship with Boehringer Ingelheim," said Fabrizio Bonanni, Dr. Chem., Amgen executive vice president of Operations. "We look forward to continuing to work closely with them to support Amgen's delivery of safe and effective medicines to patients around the world."

Amgen obtained the Fremont facility through its 2006 acquisition of Abgenix. Amgen will continue to have a key presence in the San Francisco Bay Area biotechnology community through its South San Francisco facility, one of the company's key research centers.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, psoriasis, psoriatic arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's leading companies for contract development and manufacturing of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production and global market supply can be delivered within a one-stop-shop concept. Boehringer Ingelheim has brought 18 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules, novel scaffold proteins and plasmid DNA.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. For over 125 years, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]